(NASDAQ: PRCT) Procept Biorobotics's forecast annual revenue growth rate of 21.08% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 7.57%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.48%.
Procept Biorobotics's revenue in 2026 is $337,340,000.On average, 17 Wall Street analysts forecast PRCT's revenue for 2026 to be $23,217,023,149, with the lowest PRCT revenue forecast at $21,889,992,470, and the highest PRCT revenue forecast at $24,251,385,430. On average, 17 Wall Street analysts forecast PRCT's revenue for 2027 to be $28,632,247,607, with the lowest PRCT revenue forecast at $26,767,417,270, and the highest PRCT revenue forecast at $30,071,534,658.
In 2028, PRCT is forecast to generate $34,365,340,873 in revenue, with the lowest revenue forecast at $31,924,910,263 and the highest revenue forecast at $36,767,970,868.